Overview

Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Status:
Completed

Trial end date:
2021-07-13

Target enrollment:

Participant gender:

Summary

This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.

Phase:

Phase 4

Details

Lead Sponsor:

Mylan (Taiwan) Ltd

Treatments:

Tenofovir